MCRB - Earnings call transcript Q4 2018 | Seres Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Seres Therapeutics Conference Call.

As a reminder, this conference is being recorded and will be available on Seres website for replay. And I would now like to introduce your host for today's call, Dr. Carlo Tanzi, Vice President, Investor Relations and Corporate Communications. Please go ahead.

Carlo Tanzi

good and Josh, you, morning. Thank Time with A Investors full available and fourth can Eastern and Media section company's company's XXXX press at found financial website. the AM became release year update results quarter business and the the and on morning, this of X:XX be a promise study plans, to you timing regulatory the our of recent of changes, Xb of the remind that the approval, forward-looking to of impact be like making ability relating the potential and statements, any the trial Phase sufficiency our impact clinical or cash and ECOSPOR data, microbiome operations. III to of study SER-XXX requirements therapeutics I'd support and the we'll to it's the our support development corporate expected for differ may materially. results Actual

Matt have today's I'll our Eric, be call, statements today's the only. of Eric Shaff, Dr. Kevin do section recent Horgan, of that, discussed but certain pass uncertainties, risks Q&A so. Additionally, subject the obligation morning's in Scientific forward-looking Seres represent Chief by available our prepared Matt on call On we as portion update our call to our Factors remarks Chief the I'm and disclaim Kevin future, With Officer; for and and to and and CEO; Officer. today Medical statements to this call. President under any Risk these We joined which are may made Dr. Henn, these the statements Any SEC filings. are will views Eric. of

Eric Shaff

our with Matt recently to and well strategy. by I'll change medicine our been and The the for months to clinical is progress pioneer streamlining areas therapeutics given this company's positioned been Company pipeline, I late-stage I honored I've Company and role. excited burn programs diff appointment clinical am deeply corporate to reducing ask microbiome believe the CEO Officer, our the a Seres' by efforts This more infection my scientific, will to expertise, of and colitis. for as ulcerative including and manufacturing transform immuno-oncology and reviewing give good our potential efforts opportunity our our and years the everyone. lead Chief Kevin over Phase refocused our effort. the morning, C. of brief study have Carlo, initiated several own our and strategy. four Seres substantial as includes with Chief for our President the recently Operating begin workforce within Thanks, Seres, in also refining including the discuss update ask focusing on SER-XXX cash well and period Xb corporate as initially recurrent recent as I to for of Financial SER-XXX to Officer. forward. And a I program. SER-XXX review will SER-XXX key last

Given to my the history I assessment fresh of into conduct I Company. CEO the My position operations. shareholders. for create to actions to take to required are and the intention and programs, with substantial a and of knowledge the the and value best role the role development was Seres, entered our strategy specific company's with with also patients serve advance remains objective intention took programs, Company whatever

number initial reduce actions last of Board, and runway. our company's the include cost we and extend to corporate with assessment, month, Following of our These completion operating consultation close the changes. in this structure important a implemented

on highest clinical focus evaluation of and our we program's of data, also refocused limited and made After priority to and each strategy. number to the the comprehensive company's a We potential our a care, R&D transform resources, preclinical scientific pipeline patient programs. determination

and today clear two-pronged a stated as strategy approach. be can is Our

are These readouts for clinical clinical melanoma. C. studies. are colitis, for diff achieving infection, SER-XXX we focused metastatic SER-XXX ulcerative First, and three priority for SER-XXX on for our recurrent highest

Second, focused we SER-XXX next-generation, quickly will for clinical to judiciously capabilities deploying meaningful rationally concentrate our reasons possible. on lead ulcerative number as microbiome programs, renewed enthusiasm with designed, colitis each therapeutic are Company and fermented on energy. program. advancing With resources these a of we results of behind reach our are being as There our

Our data, clinical program's commercial focused and are portfolio in compelling clinical considerable we about includes programs that and potential. each scientific are grounded, promise and optimistic

and and of and new modality, to development. developed that and success. strengthen, ultimately Stepping learning in continues clinical into have field strongly drug has and we capabilities will we believe a Seres manufacturing our what believe insights, differentiated yield Finally, understandings, results capabilities leading a probability discovery, these greater

these in the uniquely therapeutics successfully to we microbiome we're positioned believe well clinic. continue validate competencies, With to

Looking to Kevin to ahead, further and period for patients. achieve for a multiple significant Company, to pipeline. clinical to over pass with opportunities the for now we look milestones forward our the I'll shareholders, call late-stage discuss

Kevin Horgan

as review perspective human Thank my having central Medical is have the a the where dysbiosis Seres pipeline stage microbiome-based serious new, in to XXXX. you, for from late the role. therapeutics, Eric. joined of has clinical to I'm microbiome the October Chief developing Company diseases, Officer, opportunity delighted gastrointestinal

an holds and result, candidates consortia comprised treatment summarizing SER-XXX diseases of by the and address states. novel the impacts disease of Through we downstream are promise led with that modality ulcerative exploration for begin conditions, to inflammatory other immunological as infectious diseases as cancer. this evidence designed in are the as colitis for microbiome modulate of therapeutics drug approach, human great gastrointestinal develop I'll And that such live to well are microbiome. Our entirely as various biological working that bacteria, to this a processes indication.

a ulcerative of certain colitis that by metabolites amplify microbiome. bacterial body as research trigger having suggest may these produced And identified and and imbalances dysbiotic specifically been have preclinical bacteria with patients inflammation. First,

proof-of-concept SER-XXX the drug result gastrointestinal healthy published that reported administered, an remission. commensal several addition, clinical tract. of microbiota bacterial transfer derived from spores fecal candidate In orally can in human biologically have placebo-controlled colitis in ulcerative is studies sourced comprised

colitis bacterial pro-inflammatory species commensal further engrafting with of anti-inflammatory subjects that induce objective functional by and Our species. promote gut the of enhanced therapeutic bacterial integrity SER-XXX is remission responses, displace ulcerative to barrier, the

two difference Xb followed a demonstrated compared and placebo in remission Xb endpoint we criteria, daily symptomatic development accompanied have guidance. statistically in patients SER-XXX in outcome data, significant these transcriptomic on consistent a with clinical discussed study. microbiome, by XXXX XX% of Each study studies the the by Phase was with based with remission. subject remission the ulcerative as to group. effect. December, with results, achieve clinical FDA remitted, Notably, This to primary Based our for Xb both initiated compelling we our is feedback, measure by product registration weeks and positive plan to Phase as SER-XXX clinical none on support pivotal Our this eight and that metabolite endoscopic Phase serve FDA written data, with SER-XXX remission expect could the note vancomycin, stringent recommended colitis. for must treated important one significant is of is study we therapeutic a that It clinical which

lower weeks In receive arm and primary Xb vancomycin by used XX patients daily SER-XXX will regimen are Phase Consistent ulcerative vancomycin at Study most guidance, is the trial Our colitis, then pretreatment pretreatment the by randomized, efficacious with XX A, patients in two weeks. patients to the clinical is FDA high-dose followed of SER-XXX, which a Arm in weeks current study Xb of their remission, current receive patients receive the evaluate Phase high-dose a with trial. eight who dose. In Arm weeks B, also of of placebo. C approximately therapies. Arm mild most placebo-controlled, failing we induction XXX followed moderate same the three-arm, endpoint

various will primarily Xb Xb healing, is study. We encouraging The Phase induction where endoscopic study dosing. evaluate designed endpoints, also in observed our signals mucosal secondary including improvement to histological evaluate and Phase we

an receive X SER-XXX the either one recurrence maintenance sustained now The after Xb However, was important period. on have eight better recurrence. are Based that treatment cytotoxin obtained confirmed the study of All then In observed also durable at we address diff we that the C. of III drug several to to placebo diff standard engraftment primary assays. we the of studies, X study, up weeks enrollment cytotoxin the in experiencing infection with endpoint use pathogen will in rate at C. acute believe subjects very perhaps learnings we the SER-XXX exploring analysis compare to we a active ECOSPOR well the if beyond infection, living after for could microbiome diagnosis C. SER-XXX treated Xb benefit, the the entry will are seek placebo-controlled ECOSPOR III. are study lasting primary least of SER-XXX resulting diff care recurrence. study diff designed is or the recurrent diff and study, initiated diff patients. We longer-term Phase use placebo. date. who will ensures The by completed and ECOSPOR and Xb subjects result qualifying pleased and study of in completion to prior dosing. antibiotics clinical to health and III, month in understand dosing, C. the December, receive both SER-XXX infection C. ECOSPOR we for to diff randomized, subjects resistance, XXX restore at truly C. I'll turn that to designed C. reduce is a progress The SER-XXX, versus of Phase assays approximately Phase program. the is III enroll applied patients that endpoint and to dosing. are that with of the diversity rate entering

of SER-XXX in arm point X used will were of I because higher the C. one-third subjects consecutive over XX-fold failed for study current study, that's both in of is treatment total toxin of received We the diagnosis out in approximately administered III in the also will use the negative Patients the prior and SER-XXX study. diff Phase SER-XXX assay than the The three arms. in ECOSPOR who screening placebo SER days. treatment a approximately III the believe recurrence in negative accuracy dose ECOSPOR of dose that dose test. that subjects our cytotoxin increase

dozens We datasets U.S. antibiotic dose after more at of of sites therapy, on SER-XXX is engraftment expect, administration at the and SER-XXX our thereby Study this multiple the higher previous based microbiome of rapid enrollment of Canada. risk over recurrence. reducing across will ongoing diff days that C. support and

having this with to patients In enrollment. the of of experienced allow the However, study as microbiota To change to to We potentially transplantation aspects a more approval immediately, a expedite widespread protocol enrollment. operations unapproved study obtain to and continue we the largely headwinds C. infection. eight diff anticipate the of of until recurrent to eight-week fecal tactical actions. the make we've appealing SER-XXX than for this number to use January, recurring noted, We we end taken previously all wait some FDA, change implemented have have to review attribute to assessment label we that endpoint. endpoint prior primary patients, week increasing the rather open the of also will enrollment,

with we efforts, readout study. and I are SER-XXX actively scientific study statistical the evaluating changes, validity oncology taking also while now will and maintain to discuss consideration, to of structural number pass Matt to a focused into In the the the of timing, goal R&D addition, expediting all program. need our call a of

Matt Henn

modulation and six-plus significant microbiome the through understanding have Thank there been can community's tenure year Company, impact you, Over the and inflammatory the of scientific my of individuals. Kevin. human state how in disease immunological health of the advances at

assessments microbiome can our impact human clinical into translation platform reverse insights trials, by specific yielded and subjects. pharmacodynamic mechanisms insights of and Our from which pharmacokinetic have placebo-controlled therapeutics microbes the

and could we efforts. for We are response to these our lines preclinical microbiome clinical early evidence, have inhibitor of an role on several that in therapy pre-clinical discovery checkpoint leveraging therapeutics development important Based and insights in influencing cancer. believe

of or some key the blockade, in specific PD-X has labs, checkpoint microbes, demonstrated further models, convert to anti-CTL-X published Several summarize humans our inhibitor Fecal models prepared gut to bacteria various can the ability In to checkpoint how these groups inhibitor in treatments animal can diversity, response in how me from groups. microbiota sets other overall to have efficacy data as modulate data microbiota fecal from non-responsive response treatment. cancer mice and improve responsive mice. well the Let transplants. models gut and using of been demonstrated differences as from animal

melanoma, of lung general these subjects. response have in inhibitors. diversity been cancer, findings have gastrointestinal differences in metastatic the to associated human extended In been microbes kidney with Lastly, of differences settings to the and checkpoint subjects

important cancer MD scientific patients therapy. designed mimic to immuno-oncology signature SER-XXX, supported published response set findings for to modify to in found and designed meaningfully therapy, cancer collaborator, a have anti-PD-X indicating SER-XXX, is donor-derived, of from response a therapy. efforts Dr. who Turning microbiome The patient's improve checkpoint specific have our SER-XXX bacteria research basis the an to of human the of these the our lead extended to work inhibitor checkpoint to a is those checkpoint we inhibitor therapy. to Jennifer bacterial the Anderson, point the immune our by Wargo and delineate robust impact the set Analysis mechanistic signature to have level that with response sets species on microbiome microbiome can immunological in findings response refine how preclinical specific bacterial additional gastrointestinal and and continue response to impact at associated inhibitors. a data

anti-PD-X are with correlation clinical of Center. being The This will MD study approved evaluate microbiome the X:X and We anti-PD-X Phase on with is to all support safety biomarkers to and studies the or specific where T of randomized collaboration a outcome role of metastatic initiated various Institute – ratio recently study classes in date and microbiome therapy. patients including the Cancer the randomized example responses FDA a of primary CDX preclinical impacts positive cell SER-XXX in specific Cancer to Parker measures. Our subjects species an anti-tumor a microbiome or at an endpoint response as T-cells. SER-XXX explore placebo-controlled Immunotherapy trial either impacts bacterial nivolumab conducted of received Anderson melanoma, placebo. as to a and Xb therapy immunological in Patients

continue advance fermented SER-XXX of the ulcerative to microbiome colitis. for treatment a We program, designed rationally therapeutic our

We drugs XXX clinical our SER-XXX, from in incorporated design. have studies insights biological and XXX the

studies that of and that endoscopic remission engraftment As associated such clinical species example, metabolites Eric we of have the clinical financials bacterial targets utilized interest the closing as key species specific dynamics species, UC that back and and comments. these the in provide and functional of we as efficacy learnings to across with from produce with pass advance are call correlate program. modulate to now can this that subjects I'll cover improvement

Eric Shaff

fourth reported Matt. Thanks $XX.X G&A against $X.X were and the Seres cash cash, The quarter the $XX.X same QX equivalents in expenses year. for of the the in XXXX, inclusive driven the clinical increase fourth net loss from received million fourth to the ongoing $XX.X with excluding ended company's or into net net for year. to payments, Seres of resources quarter fourth the net same during was prior as activities of for the and net company's fund XXXX. period collaboration by and XXXX, in Based $XX and expenses, the incoming year. operating personnel cash $XX.X of million Seres as development The for Revenue milestones under primarily therapeutics R&D with quarter collaboration current reported a expenses Science. the compared associated over million potential loss Health of net in million $XX.X as quarter fourth million, progress for Nestlé will Health million quarter company's time, related increase was same of loss full revenue for $X.X on the compared this expected to microbiome investments to BD collaboration of for in net a for development a million, CapEx Nestlé XXXX. expenses Health the platform. loss of $XX were of XXXX balance was quarter $XX.X quarter The the fourth recognized loss cash, in $XX the investments. compared flows based as on Nestlé the the to are million with in company's $XX.X with Science. Science. was operating expenses approximately requirements, the QX period the recognized compared million achieved fourth cash prior a year million figure in future million million. the plan, cash and inclusive loss quarter equivalents primarily period company’s in The be milestones with to cash milestone

to moment as to we Now past before I just this well recapping looking Q&A, move ahead. period, move I want a spend to – as before

we As programs of company what meaningful believe have patient are we heard, to benefit, with a highly number, refocused you have and value. on create select the provide opportunity exciting substantial

As we driving a principal, possible. as and these quickly company operating are on focused programs execution forward, as

we Our expeditiously toward program, in eyes the capabilities have on the to each place and clinical readouts ensuring that of each these drive for events. team,

as in be based we the We strong know have the status possible, regarding a on as We to support are operational like Nestlé. also of today, partner clear fortunate also would corporate our SER-XXX of we what Phase the expect projections, to obtain pipeline. SER-XXX study, expect we Xb study by Based XXXX. of to results complete on Xb and Phase in current the XXXX, mid enrollment to

continue and study, soon we working you now changes our open as complete provide line that diligently we X with assessment for and Phase any as questions. to We will an to let’s to recruit the study mentioned, as are Operator, of SER-XXX Kevin the possible. update

Operator

you. Instructions] Mark Company. first question [Operator & comes of Our Thank from Oppenheimer Breidenbach

question. You with your proceed may

Mark Breidenbach

Kevin. the taking guys, questions. for one Hey, for good morning and Maybe thanks the first

negative I think who ECOSPOR for are of are you for that failing their cytotoxins. into in heard entry screening one-third due subjects the III mentioned study to I touching

Thanks. literature? failing actually the rate cytotoxins of second all, infection artificially are the for of And see First than we negative higher a incidence us that of sense for? other tests CDI recurrent if what you two-thirds all, give maybe can high for in implying largely – wondering, are are screening what I’m the of the commonly

Kevin Horgan

pretty remarkable, frequently to the toxin with how we respect is it’s explanation only that it’s see pretty the negativity. screening, So reasons really – for

other I like subjects And complete spectrum PCR sensitivity two the your when or tests. reasons, it’s and that of is toxin kind of for our to significant at disease recurrent that no specificity and regard sense tests, inevitably, recurrent that to that other the has patients versus factor individual are the define it is diagnosing PCR using based accurately If over approaches, when the think, I reasons. disease. amount There failing I And on be – of second we’re thing dominant entire question, out. is the – a to of one of variety you disease science think, look of there with stands a other real – key confident assessed is toxin diagnosis there we’re think,

Eric Shaff

I’ll that numbers this Mark, And Maybe – the which cases, to incredibly opposed as comment to by the believe issue, We answer, that approach to important is add really inadequate. and we’re healthcare using obviously cytotoxin is Eric. Yes, I wholly assessments believe agree in just difficult I And is, unless add and PCR. those issue, an would leading Kevin’s C. with. have around potential thing, one diff we in needs, high in you’re field question using and orphan Kevin’s that whether the which really cytotoxin not. we space really many medical SER-XXX population they’re efficacy we the recurrent you they throw are at around particular solutions are to for approaches, the people other looking are as as believe accurate, unmet today when patient with are disease

So add wanted I that. just to

Mark Breidenbach

originally a trial you are an why was back it scaled X-arm some that Okay. that from transplant a seem used on little the going comparing enroll Can one me, what was changes included to I to fecal All I remember, that’s comment XX SER-XXX helpful. of against down sort. we help, last proposed design that patients? year. with the patients notice has right, arm be can’t of trial a just One to X-arm XX design been and but was to a it targeting from the last bit

Eric Shaff

answer Yes, Mark, to this is Eric, I’ll that. ask Kevin

Kevin Horgan

SER-XXX. program program active Yes, the I reflects evaluating mean, of that – that I design actually moment – just the think at it It’s the is of the unchanged. the the fundamental the component is component is

Mark Breidenbach

include in terms see future the – another we does in might Okay. But that imply would it? that added of arm

Kevin Horgan

Yes, yes, absolutely.

to committed in moment the XXX is be that component conducting enrollment study. to of at FMT just the arm. right We’re happens the It the

Mark Breidenbach

for Okay, got you taking it. Thank questions. the

Operator

Thank you. And Shibutani Cowen. Chris of from our next question comes

your with You may proceed question.

Pam Barendt

for the hi. a Pam Thanks couple Chris. questions. is This update. I Yes, had of for on

mentioned this on more Thank you changes. potential on elaborate investigators? you structural sites, bit, you. First, XXX, a study Could little more

Eric Shaff

Yes. Thanks for question. the

approaches, So about thinking major how XXX. there’s two we’re really

The first operational it’s perspective. is, from an

commented at. before, those looking possible all regarding remarks. every we’ve prepared we’re As And the directly into to of enrolling we’re looking levers in those one the the that increase of study. FDA in not patient patients but we’ve that our But amendment enrollment. of Kevin agreed mentioned to at open-label one the lever certainly one, that’s mentioned

the and We clinical stone the continue study to patients. unturned enroll we those quickly make sure relating is that no can how in operations to

leadership changes the that at it seen certainly of trial after late-stage study trial expedite we design decisive made, reaching of results. corporate that’s which before, and component we continue other changes what will are the Certainly, design here. alternatives not in afraid mentioned really we to endpoints, we’ve The and relating make the ways clinical the look to we and case and the be I is, think to given alter you’ve shortly can here, decisions that

we then those get updates. So with will if updates, additional to you back are there

Pam Barendt

the very On trial one like? of you, trial, pivotal any FDA is ask second or discussions helpful. And two moved look XXX, Thank pivotal one trials, more. with if there Thank what possibility very I if really much. you would have just the towards just can

Eric Shaff

– our disclose by of I’ll I’ll don’t compelling But be this have would Kevin is FDA. pivotal commentary. this we the with kind today, as is, that Yes, add of two to be one And stand with trials. one the start we interactions this of results, here day-to-day the expectation Eric. would ask saying, we

Kevin Horgan

Yes.

be in novel standard I inflammatory bowel a for two in agree, and ulcerative the particular, mean, in will disease registration pivotal of So I therapeutic general colitis trials.

general second And are trial development bowel induction, study that maintenance one for study is exploring an trial achieve and indication. the the regimens. it’s of would trials we required whereas only would one are the is the maintenance obtain dividends maintenance of mentioned, a colitis the particular, pivotal a that focus current in inflammatory we of And for I ulcerative in to induction an order specific regimen in study, indication. be maintenance obtain As indication disease two paradigm pivotal drugs a required for to to pivotal the

configured And program currently directly those our so requirements. fulfill as will

Pam Barendt

it. Got Thank very much. you

Operator

And Thank Chardan. comes question you. our Feehley next Taylor of from

You may with question. proceed your

Taylor Feehley

everyone. Thanks I morning, my implemented. protocol been was Kevin, call. for of Good taking discussed hoping on clarification have for you a bit the little changes

of I for if but correctly, roll to be of recurrence, time So, ahead that weeks to get to in new how patients many patients weeks pretty how understood of now to field about this recur for recur seems point, open-label patients sense over it a would standard trying is who was fall common into I wondering eight the Eight can testing XXX. the use ahead of group?

Eric Shaff

first XX of timing the within to XX the skewed few recurrence heavily weeks is days. towards The days first

has no, primarily the reasoning assess to wanted I that is open that, investigators obviously extension, that that in think go to, it’s that able see they whom and as of eight-week to our into enable recurred, we the So period, out to with us is recur probably label would and would, potential they patients patients relevant. of has the this has they a the the there’s be enrollment. they that proposal FDA’s FDA make suspect that number confidence patients to approach to our will modeled fecal change dialogue directly informed after quite notable to that factor a haven’t this a extension. safety. we And original the the reflection microbiota sense and safety label And open be help allowed to that was that this our the would patients with there, our flexibility go dialog had issue. once whole was backdrop this it’s change to whole substantial transplant following And to is – for the resonated approach But of to precisely, but into were something the that full FDA resistant this a

Taylor Feehley

that much added a question. up FMT follow you thank the on bit And so for little color. Yes, wanted I to

are ongoing approved if So two cost regulators skewed tracks, not regulators, you’ve York medicine on anyone the on but the had New was relative in indicated or other other in debate? to one I an weekend. some concerned on was physicians of debate perception And Times favoring any over way the or or comments whether are The considerations comments that FMT. toward wondering certainly the your Certain the of of the highlighted pricing

Eric Shaff

Thanks I Taylor. that Yes, I for the by question. about great thing think, a saying, diff. it’s talking C. would start are people

extremely costly segment there the is I a are SER-XXX, it’s as for think, with to great disease, especially patient thing. I you’re are solutions in patients and system the and it’s This serious a recurrent inadequate as are mentioned, today if looking just we the space. at

the And question clinical away. term GMP serve strongly in safety So will short the on procedures for idea FDA is and doesn’t we that feel therapy approved think, of that we anything right? long But way efficacy, certainly patients to what’s in best And serve the term, on or unregulated speculating approved the right. that regulated speculating studies, sense, go our uncontrolled therapy, helps well-controlled make is the through with belief to patients. FDA and the is an manufactured patients, way best

I’ll maybe to ask further. comment So Kevin

Kevin Horgan

deviations the are United informed remarkably FDA that unnecessary other States. and enable they’ve and XX medical here to years, providing to outside those XX put make paradigms approach. with regulatory decisions there patients patients well. it’s the and the with I system really think, And key physicians need, data and last of when And that agencies can the patients therapies make at that from been think, is under I the Yes, that, for has a of worked informed evaluation happy are paradigms that the they thing auspices or decision. the and physicians over our very risk And we’re

diagnosis. we’re science, pushing having accordance – with topic should outcomes something informing that’s think rigorously – space, and is is transparent about for carefully And not the with taking This but very the that We’re clinical rigorous toxin think the using the the frontiers way. really – we’re in to trials of the for patients and FDA. in inform in practice a in is optimize dialog this reflected we design only – helping this I things we’re very and clinical of

Taylor Feehley

much those you comments. thank for so Great,

Eric Shaff

we look for question forward participating conference Thanks tomorrow. and Taylor the to microbiome the in

Operator

John comes And question from Canaccord. of our you. Newman next Thank

You your question. may proceed with

John Newman

have my Thank answered. been All questions you.

Eric Shaff

Thank you, John.

Operator

our Thank Wainwright. Bernardino of comes you. Vernon And next from question H.C.

may question. with You proceed your

Vernon Bernardino

my taking questions, SER-XXX. on congrats for thanks the and initiation Hi, of

of couple a Just questions.

– just you. measures SER-XXX, time microbiome mechanism in Regarding the for study, of do of diseases? take these you the definition the your I SER And with – will the for that frame ECOSPOR have approach study? far as perhaps changes what with expect a the lastly, the positive you SER-XXX pace changes to guess seen studies coming patient have you also but, action to to then for What of you be enrollment? XXX. our of type with then in any structural III as And as Thank looking seen perhaps

Eric Shaff

Vernon. Yes,

Maybe take questions. I’ll on XXX. which first three progress is in one, the So

also ensuring the and try operationally detail up taking we’ve fresh at CMO looked provided new enrollment a I not look about Kevin’s speed to in that alternatives. and every operations have enrollment, lever and again, includes frankly exhaustive say that We can clinical on to our our what we’re to that, arrival guidance thinking is as at possible or date,

think which, more that mentioned patients attractive one of it is way enrollment, Kevin increasing that protocol we possibility speeding a the we trial. there remarks, is enrollment, So in up as the in enter making that do opening amendment of think, the to example for his

question to second related I’ll Your that mechanism, maybe Matt comment to ask and one. on

Matt Henn

Yes, no problem.

So was think XXX question was the I question. the It from XXX. mechanism both unclear – around and and

So briefly. address I’ll both

that the the C. And repair pathways inflammatory change as And this action are connect mechanisms we and as produce out including are to that and in generate that’s is with as respect specific and composition, the further microbes So the there been of well to we UC that with to see various that acid gut, cetera. immunological bile identify diff. in of of metabolites, ability in genetic been a primary and not. competition in and remission, case, very believe One pathways believe SER-XXX, in interesting are changes there, ability data SER-XXX we to in compete in towards, barrier ones and epithelial bacteria. of as is mechanisms others profile as the integrity mechanisms changes respect two down of SER-XXX key with to through said use of to metabolic that we our ability that XXX, in ability able they against et really metabolism the as we to important are therapeutics and mechanisms of done as known the associated different are the play. then such subjects, metabolites and can are to particular that are lot carbohydrate ability to obtaining well these action bacteria we’ve C. different the example, diff and changes. And are to that secondly, we to the well as the various basically with With different which important are respect favorable we’ve the designing inflammation, for tap

Kevin Horgan

we I’d trial. And think you But, know, from XXX, in the way on I we of timing expect started And detail just that your additional that receive question and might just XXXX. as the course, to get further guide data XXX. we in we as we related it. readout Vernon, for may to last additional get perhaps, reiterate

initial guidance now, we’ll with that for So we past. done the overtime that and provide programs in other may we’ve refine as

Vernon Bernardino

helpful. you. that’s Thank Terrific,

Operator

Thank you. I call now does remarks. back over to Q&A. Seres our any the conclude like to for would And that turn closing Therapeutics,

Eric Shaff

Oppenheimer’s upcoming on New tomorrow York, Conference for March everyone attending interest to us your I XX, Microbiome Therapeutics. So in giving Summit and in York Seres Chardan thank conferences, in Medicine March you, Care Sciences continued Boston several morning, the XX. Conference let operator, will Cowen’s we New and that and for this Health including on know be your you Care in just want thanks Health for time

connecting to forward look with we soon. you So of many

So we’ll end today’s Thank day. call and have you. a great

Operator

participating conclude conference. disconnect. and all and you today’s ladies gentlemen, for Everyone in day. This wonderful you does you, program, thank today’s a Thank may have

Seres Therapeutics (MCRB) 6 Mar 192018 Q4 Earnings call transcript